Literature DB >> 25715678

Dynamic changes of nuclear RNA foci in proliferating DM1 cells.

Guangbin Xia1, Tetsuo Ashizawa.   

Abstract

Nuclear RNA foci are molecular hallmarks of myotonic dystrophy type 1 (DM1). However, no designated study has investigated their formation and changes in proliferating cells. Proliferating cells, as stem cells, consist of an important cellular pool in the human body. The revelation of foci changes in these cells might shed light on the effects of the mutation on these specific cells and tissues. In this study, we used human DM1 iPS-cell-derived neural stem cells (NSCs) as cellular models to investigate the formation and dynamic changes of RNA foci in proliferating cells. Human DM1 NSCs derived from human DM1 iPS cells were cultured under proliferation conditions and nonproliferation conditions following mitomycin C treatment. The dynamic changes of foci during the cell cycle were investigated by fluorescence in situ hybridization. We found RNA foci formed and dissociated during the cell cycle. Nuclear RNA foci were most prominent in number and size just prior to entering mitosis (early prophase). During mitosis, most foci disappeared. After entering interphase, RNA foci accumulated again in the nuclei. After stopping cell dividing by treatment of mitomycin C, the number of nuclear RNA foci increased significantly. In summary, DM1 NSC nuclear RNA foci undergo dynamic changes during cell cycle, and mitosis is a mechanism to decrease foci load in the nuclei, which may explain why dividing cells are less affected by the mutation. The dynamic changes need to be considered when using foci as a marker to monitor the effects of therapeutic drugs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25715678      PMCID: PMC4439307          DOI: 10.1007/s00418-015-1315-5

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  42 in total

Review 1.  Structures of trinucleotide repeats in human transcripts and their functional implications.

Authors:  Anna Jasinska; Gracjan Michlewski; Mateusz de Mezer; Krzysztof Sobczak; Piotr Kozlowski; Marek Napierala; Wlodzimierz J Krzyzosiak
Journal:  Nucleic Acids Res       Date:  2003-10-01       Impact factor: 16.971

2.  Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching.

Authors:  Raman Parkesh; Jessica L Childs-Disney; Masayuki Nakamori; Amit Kumar; Eric Wang; Thomas Wang; Jason Hoskins; Tuan Tran; David Housman; Charles A Thornton; Matthew D Disney
Journal:  J Am Chem Soc       Date:  2012-03-05       Impact factor: 15.419

3.  Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients.

Authors:  Chantal Sellier; Frédérique Rau; Yilei Liu; Flora Tassone; Renate K Hukema; Renata Gattoni; Anne Schneider; Stéphane Richard; Rob Willemsen; David J Elliott; Paul J Hagerman; Nicolas Charlet-Berguerand
Journal:  EMBO J       Date:  2010-02-25       Impact factor: 11.598

4.  Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat.

Authors:  A Mankodi; E Logigian; L Callahan; C McClain; R White; D Henderson; M Krym; C A Thornton
Journal:  Science       Date:  2000-09-08       Impact factor: 47.728

5.  Huntington's disease--like 2 is associated with CUG repeat-containing RNA foci.

Authors:  Dobrila D Rudnicki; Susan E Holmes; Mark W Lin; Charles A Thornton; Christopher A Ross; Russell L Margolis
Journal:  Ann Neurol       Date:  2007-03       Impact factor: 10.422

6.  Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy.

Authors:  Xiaoyan Lin; Jill W Miller; Ami Mankodi; Rahul N Kanadia; Yuan Yuan; Richard T Moxley; Maurice S Swanson; Charles A Thornton
Journal:  Hum Mol Genet       Date:  2006-05-22       Impact factor: 6.150

Review 7.  Pathogenic mechanisms of myotonic dystrophy.

Authors:  Johanna E Lee; Thomas A Cooper
Journal:  Biochem Soc Trans       Date:  2009-12       Impact factor: 5.407

8.  Pentamidine reverses the splicing defects associated with myotonic dystrophy.

Authors:  M Bryan Warf; Masayuki Nakamori; Catherine M Matthys; Charles A Thornton; J Andrew Berglund
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-12       Impact factor: 11.205

9.  Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules.

Authors:  Jessica L Childs-Disney; Ewa Stepniak-Konieczna; Tuan Tran; Ilyas Yildirim; HaJeung Park; Catherine Z Chen; Jason Hoskins; Noel Southall; Juan J Marugan; Samarjit Patnaik; Wei Zheng; Chris P Austin; George C Schatz; Krzysztof Sobczak; Charles A Thornton; Matthew D Disney
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues.

Authors:  K L Taneja; M McCurrach; M Schalling; D Housman; R H Singer
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

View more
  13 in total

Review 1.  The Histochemistry and Cell Biology omnium-gatherum: the year 2015 in review.

Authors:  Douglas J Taatjes; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2016-02-15       Impact factor: 4.304

Review 2.  Modeling simple repeat expansion diseases with iPSC technology.

Authors:  Edyta Jaworska; Emilia Kozlowska; Pawel M Switonski; Wlodzimierz J Krzyzosiak
Journal:  Cell Mol Life Sci       Date:  2016-06-03       Impact factor: 9.261

Review 3.  RNA toxicity and foci formation in microsatellite expansion diseases.

Authors:  Nan Zhang; Tetsuo Ashizawa
Journal:  Curr Opin Genet Dev       Date:  2017-02-14       Impact factor: 5.578

4.  Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1.

Authors:  Siham Ait Benichou; Dominic Jauvin; Thiéry De Serres-Bérard; Marion Pierre; Karen K Ling; C Frank Bennett; Frank Rigo; Genevieve Gourdon; Mohamed Chahine; Jack Puymirat
Journal:  Gene Ther       Date:  2022-01-25       Impact factor: 5.250

Review 5.  Human induced pluripotent stem cells for monogenic disease modelling and therapy.

Authors:  Paola Spitalieri; Valentina Rosa Talarico; Michela Murdocca; Giuseppe Novelli; Federica Sangiuolo
Journal:  World J Stem Cells       Date:  2016-04-26       Impact factor: 5.326

6.  A low absolute number of expanded transcripts is involved in myotonic dystrophy type 1 manifestation in muscle.

Authors:  Anke E E G Gudde; Anchel González-Barriga; Walther J A A van den Broek; Bé Wieringa; Derick G Wansink
Journal:  Hum Mol Genet       Date:  2016-02-16       Impact factor: 6.150

Review 7.  Myotonic Dystrophies: State of the Art of New Therapeutic Developments for the CNS.

Authors:  Genevieve Gourdon; Giovanni Meola
Journal:  Front Cell Neurosci       Date:  2017-04-20       Impact factor: 5.505

Review 8.  Cells of Matter-In Vitro Models for Myotonic Dystrophy.

Authors:  Magdalena Matloka; Arnaud F Klein; Frédérique Rau; Denis Furling
Journal:  Front Neurol       Date:  2018-05-23       Impact factor: 4.003

9.  A potential role of extended simple sequence repeats in competing endogenous RNA crosstalk.

Authors:  Tomasz M Witkos; Wlodzimierz J Krzyzosiak; Agnieszka Fiszer; Edyta Koscianska
Journal:  RNA Biol       Date:  2018-11-05       Impact factor: 4.652

10.  Activation of the interferon type I response rather than autophagy contributes to myogenesis inhibition in congenital DM1 myoblasts.

Authors:  Milena Rizzo; Pascale Beffy; Renata Del Carratore; Alessandra Falleni; Virginia Pretini; Romina D'Aurizio; Annalisa Botta; Monica Evangelista; Andrea Stoccoro; Fabio Coppedè; Denis Furling; Marcella Simili
Journal:  Cell Death Dis       Date:  2018-10-19       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.